Global economies have started reopening, yet the battle against COVID-19 wages on. Researchers and healthcare organizations are racing to develop a vaccine capable of preventing COVID-19 infections, and Wall Street is speculating as to who will emerge victorious.To this end, investor focus has locked in on Inovio Pharmaceuticals (INO). On June 4, Inovio, the International Vaccine Institute (IVI) and Seoul National University (SNU) Hospital announced they would collaborate on the initiation of a Phase 1/2 trial of INO’s COVID-19 DNA vaccine, INO-4800, in South Korea later this month. This will mark the country’s first COVID-19 vaccine clinical study, with it …read more
Source:: Yahoo Finance
